OS Therapies announced it will present 2.5-year overall survival data from its Phase 2b OST-HER2 trial for pulmonary metastatic osteosarcoma at the 2026 ASCO Annual Meeting. OST-HER2 is a gene-edited, listeria-based immunotherapy targeting HER2 mutations, designed to prevent or delay cancer recurrence after surgery. The therapy has received multiple FDA and EMA designations, including Orphan Drug and Fast Track, and the company aims to file for U.S. accelerated approval and conditional marketing authorizations in Europe and other regions in 2026. Positive earlier trial results showed significant benefits in event-free and overall survival, highlighting OST-HER2's potential as a new treatment for osteosarcoma.
ZetaChain introduced Anuma, its first consumer AI product that offers a private, encrypted memory layer allowing users to maintain their context across various AI models like ChatGPT, Claude, and Gemini. Powered by the ZETA token, Anuma enables users...
Proficient Auto Logistics announced its participation in the William Blair Growth Stock Conference on June 2, 2026, where its CEO and CFO will meet with investors. The company will report its second quarter 2026 financial results on August 10, 2026, ...
Constellation Software Inc. has finalized its acquisition of a majority interest in Derbysoft Holdings Limited through its Juniper Group operating unit. DerbySoft, which includes PKFARE, will continue to operate independently under CEO Ted Zhang. Thi...
Hewlett Packard Enterprise (HPE) shares soared 36.4% after hours following a strong Q2 report that beat earnings and revenue estimates, driven by robust demand for AI infrastructure and expanded networking products. CEO Antonio Neri highlighted recor...
Silver Point Capital has co-led a $200 million secured term loan financing for Liberty Puerto Rico subsidiaries to support their liquidity needs. The loan has a fixed interest rate of 12% per annum and matures in 2030. Of the total facility, $150 mil...
